Zimmer Biomet Inc. (ZBH)

Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations.

Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 drug overhang. The 2015 Zimmer Biomet merger hasn't been fully delivered, but ...

Zimmer Biomet benefits from its diversified portfolio outside of core orthopedics and the company's strategic investments in attractive, higher-growth segments.

On Thursday, Zimmer Biomet Holdings, Inc ZBH reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q4 2024 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants David DeMartino - Senior Vice President-Investor Relations Ivan Tornos - Pres...

Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street...

Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar.

Zimmer Biomet (ZBH) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $2.20 per share a year ago.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zimmer (ZBH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quar...

ZBH's Hips business is expected to have witnessed growth banking on its suite of navigation solutions in direct anterior stems and surgical impactors.